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we would propose that stages of melanin formation that require
tyrosinase enzymatic activity will proceed optimally at near neutral
pH and that it is the p-locus product that functions to provide these
conditions. It is possible that the P-protein creates a neutral local
microenvironment and this is important in maintaining the high
molecular weight melanogenic complex of tyrosinase, TRP-1 and
-2. This would explain the absence of this complex in p-locus
mutated mouse cells (Lamoreux et al, 1995).
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A Novel a(± 4)-to-g Acceptor Splice Site Mutation Leads to
Three Bases Insertion in Ferrochelatase mRNA in a Patient
with Erythropoietic Protoporphyria
To the Editor:
Erythropoietic protoporphyria (EPP; MIM 177000) is an inherited
disorder caused by a partial de®ciency of ferrochelatase (FECH),
the last enzyme in the heme biosynthetic pathway (McKusick,
1998). In EPP patients, protoporphyrin accumulated in red blood
cells, skin, liver, and other organs causes photosensitivity and
occasionally life-threatening liver failure. Flushing, blister forma-
tion, pigmentation, and scarring of areas of skin exposed to sunlight
are the dermatologic symptoms of EPP (Todd, 1994). The level of
protoporphyrin in erythrocytes and feces is increased, but usually it
is not secreted in the urine. Human FECH cDNA contains
2443 bp. The FECH protein consists of 423 amino acids and has a
molecular weight of 40±42 kDa (Nakahashi et al, 1990). The
FECH gene spans at least 45 kb on the chromosome 18q21.3 and
contains 11 exons (Taketani et al, 1992). Over 38 mutations in the
FECH gene in EPP patients have been reported (Rufenacht et al,
1998). The characteristic FECH gene mutation in patients with
liver failure had been thought to be abnormal splicing leading to
exon skipping; however, it has been found that other mutations
resulting in a null allele are involved in EPP pedigrees with liver
complications (Rufenacht et al, 1998). Here we report a novel
mutation in the exon±intron boundary in a case of EPP in which
FECH activity in lymphocyte is 39.4% of normal.
A 23-y-old Japanese male who had photosensitivity visited our
University Clinic for a thorough examination. He had the ®rst
symptoms of painful erythematous swelling on his face, hands, and
feet at the age of 15 when he came home from a school trip. His
symptoms were getting worse. His parents were asymptomatic and
he had no siblings. There was no history of photosensitivity in
other family members. Routine blood test values and liver function
data were within normal limits. The minimal erythema doses of
ultraviolet (UV) A and UVB were normal. Examination of the
urine with a Wood light revealed no ¯uorescence. Blood
protoporphyrin was 1424 mg per dl (30±86), blood coproporphyrin
2 mg per dl (< 1), and urine coproporphyrin 30 mg per Gcreatinine
(47±151). Lymphocyte FECH activity in the patient measured by
the method (Li et al, 1987) was 24.4 nmol zinc-mesoporphyrin
formed per mg protein per h in contrast to 62.0 in a normal
control.
After informed consent, blood samples were collected from the
patient. Total RNA was extracted from the white blood cells by
the TRIZOL method (Life Technologies, Gibco BRL,
Gaithersburg, MD) and was subjected to oligo(dT) primed
cDNA synthesis using M-MuLV reverse transcriptase (RT)
(Amersham Pharmacia Biotech, Cleveland, OH). One microgram
of the ®rst strand cDNA was used as a template for PCR
ampli®cation with the primer pair, FCH-F; 5¢-
CGGGCCGAGGCTGCCCAGGC-3¢ and FCH-E5-B; 5¢-CTG-
TGGTGGAGCAGCTGTACTG-3¢ [cDNA nucleotide positions
±21~±2 and 567±588 (GenBank accession no. D00726), respect-
ively]. Ampli®cation conditions were 94°C for 3 min, followed
by 35 cycles of 94°C for 1 min, 62°C for 1 min, and 72°C for
2 min, and then ®nal extension at 72°C for 5 min. The PCR
product (619 bp) was cloned into pCR2.1-TOPO TA-cloning
vector (Invitrogen, Carlsbad, CA). Sequencing was carried out
using the Dye Terminators Cycle Sequencing Ready Reaction
(Perkin Elmer, Warrington, U.K.) on an ABI 310 genetic analyzer.
To con®rm the heterozygosity of the mutation, direct sequencing
was done with a smaller size of PCR product with primers, E4DF2;
5¢-AAGAGCAGTACCGCAGGATT-3¢ [cDNA nucleotide pos-
ition 359±378 (GenBank accession no. D00726)] and FCH-E5-B.
Genomic DNA was extracted from white blood cells with a
QIAamp Blood Kit (Qiagen, Hilden, Germany). Genomic DNA
from normal healthy Japanese people was used as controls. Speci®c
primers, FCint4up; 5¢-CTCTGAGGAATCTATATAAGG-3¢
(unpublished data) and FCex5dn; 5¢-GTGAAAGCAATAGCC-
CTTTC-3¢ [cDNA nucleotide position 547±566 (GenBank
accession no. D00726)] were designed for ampli®cation of the
intron 4±exon 5 boundary. Ampli®cation conditions were 95°C for
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1 min, followed by 35 cycles of 95°C for 40 s, 58°C for 40 s, and
72°C for 1 min, and then ®nal extension at 72°C for 3 min. PCR
products (163 bp) were gel puri®ed (Qiagen) and directly
sequenced. The mutation was veri®ed with the restriction enzyme
BfaI, which digests the site newly created by the mutation IVS4±4,
a®g (CTAG instead of CTAA). Three microliters of puri®ed
PCR products (163 bp) were digested at 37°C for 3 h with 0.5 U
of BfaI in a 15 ml reaction mixture and then electrophoresed in a 3%
agarose gel. The gel was stained with ethidium bromide and
photographed under ultraviolet light.
For bacterial expression of FECH, the PCR products of protein
coding region of FECH cDNA from the EPP patient were digested
with BamHI and PstI, and ligated into BamHI-PstI digested pAR-
HF (Okuda et al, 1994). The plasmid carrying mutated FECH
cDNA was obtained (pAR-HFM). The plasmids were transformed
into E. coli BL21. The FECH activity was measured using
mesoporphyrin IX and zinc acetate, as described (Okuda et al,
1994).
The sequence of the subcloned cDNA revealed that three bases
(TAG) were inserted between exon 4 and exon 5 that did not affect
the frame (Fig 1A). As a result, valine (V) was inserted between
threonine (T) at codon 154 and alanine (A) at codon 155 in the
patient's FECH (Figs 1A, 2B). Five out of 11 clones carried this
insertion. The direct sequence of the RT-PCR products showed
overlapping sequences after the sequence of exon 4, indicating that
the patient had both normal and abnormal spliced mRNA species
(Fig 1B). Therefore, we examined the genomic DNA and found,
as expected, an a(±4)-to-g transition mutation at the 3¢ acceptor site
of intron 4 in the FECH gene (data not shown). Segregation of
PCR products from the genomic DNA by BfaI restriction enzyme
digestion revealed that the patient and his mother were hetero-
zygous for this mutation, whereas the patient's father and a normal
control did not carry the mutation (Fig 2A). This mutation was
not found in 50 normal Japanese individuals examined by the
PCR-BfaI digestion method and it was not likely to be a
polymorphism.
To demonstrate that the additional amino acid has a functional
effect, the recombinant proteins were expressed in the bacterial
expression system and its enzyme activity was measured and
compared with wild-type protein. The activity of pAR-HFM-
Figure 1. Detection of the mutation of FECH cDNA in the EPP
patient. (A) Consequence of the splice site mutation at the mRNA
level. Sequencing of the subcloned RT-PCR product (619 bp) revealed
a 3 bp insertion in ®ve of 11 clones (upper panel). Lower panel shows the
normal sequence. Both chromatograms indicate reverse (antisense)
sequences. (B) Analysis of the aberrant transcript caused by the mutation
IVS4±4, a®g by direct sequencing of the RT-PCR product.
Overlapping sequences after exon 4 indicates the existence of both
aberrant and normal transcripts.
Figure 2. DNA diagnosis in the family and schematic
presentation of the aberrant transcripts caused by the mutation
IVS4±4, a®g. (A) A scheme of BfaI (B) sites (CTAG) in PCR products
(163 bp) from the genomic DNA (left panel). Figures inside rectangles
refer to sizes (bp) of digested fragments. The mutation, designated
IVS4±4, a®g, creates a site for the restriction enzyme BfaI, which was
used to verify the mutation. BfaI digestion analysis of the PCR product
for each individual is shown below the corresponding symbols in the
pedigree (right panel). Black square indicates the patient. The mutant
allele corresponds to 87 and 54 bp fragments, whereas the normal allele
corresponds to 141 bp. M, molecular marker; C, control individual. (B)
The exon-intron organization of the sequence spanning the region from
exon 4 to exon 5 of the FECH gene. Normal splicing is illustrated
above the gene, and aberrant splicing is shown below the gene. Insertion
of the ``TAG'' gives rise to the insertion of a valine residue between the
threonine and alanine. The mutant nucleotide and amino acid are in
bold type.
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transformed bacteria was similar to that of a mock cDNA-
transformed one, indicating that the mutated FECH did not exhibit
any activity (Fig 3).
The location of mutations in the FECH gene is highly
heterogeneous and there are no mutation hot spots. The predom-
inant type of FECH gene mutations are single-nucleotide substi-
tutions in the coding region (42%), followed by exon skipping
(34%) and small deletions and insertions (21%) (Rufenacht et al,
1998). This is the ®rst instance of an amino acid insertion in the
FECH protein. The transition of A to G at 4 bases from the 3¢
terminus of intron 4 (IVS4±4, a®g) leads to in-frame insertion of
three bases in ferrochelatase mRNA (Fig 2B). It is suggested that
recognition of the 3¢ splice site a(±2)g(±1) by the splicing factor
U2AF35 (Wu et al, 1999) was disturbed due to the mutation at
a(±5)g(±4). As a result of misreading the 3¢ acceptor splice site,
aberrant splicing would occur. Aberrant splicing has been classi®ed
into four types: exon skipping, cryptic site activation, intron
retention, and new site creation (Nakai and Sakamoto, 1994). Our
case corresponds to the last type. The observed frequency of point
mutations at position ±4 within 3¢ splice sites was 0 among 101
different point mutations in the vicinity of mRNA splice junctions
(Krawczak et al, 1992). To our knowledge, a mutation at position
±4 that generated a novel acceptor splice site in FECH gene is rare
and critical for this patient.
It is not too surprising that his mother was asymptomatic, though
she was found to be heterozygous for the mutation. The reason is
that EPP is thought to be inherited with low clinical penetrance
and may be considered as an inherited disorder that does not strictly
follow recessive or dominant rules (Gouya et al, 1996). Other
factors such as the expression level of the wild-type allele and
environmental effects may contribute to modulation of the
phenotype.
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Mechanical Stress Induced by Hyperosmolarity
To the Editor:
We have recently read the article by Dascalu et al (2000) in which
our work was cited and hereby wish to comment on what we
believe to be inaccuracies in the interpretation of our cited article.
Several lines of evidence have supported the assumption that
mechanical forces applied to human cells are able to modulate
fundamental events like proliferation and differentiation (Chen et
al, 1997). Our group has already shown that different qualities of
mechanical stimuli provoke different cell responses (GoÈrmar et al,
1990; Kippenberger et al, 1999, 2000a, b). The application of cell
stretch to human keratinocytes in vitro ampli®es the proliferation
cascade, whereas mechanical pressure was shown to increase
differentiation signals. In the October 2000 issue of the Journal of
Investigative Dermatology, Dascalu et al subjected human keratino-
cytes to hyperosmotic stress and discussed the cellular responses as a
Figure 3. Demonstration of a functional mutation with bacterial
expression assay. Mutated FECH protein expressed in E. coli BL21
has no residual activity. Data are shown as the percentage of the FECH
activity with normal control, based on the mean 6 SD of triplicate
experiments. The average activity of cell extracts from pAR-HF
transformed bacteria was 10.2 nmol zinc-mesoporphyrin formed per min
at 37°C.
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